

1 **The therapeutic effect of intra-articular facet joint injection with normal saline as**
2 **a comparator for chronic low back pain: a systematic review and meta-analysis**

3

4 Tanawin Nopsopon,¹ Krit Pongpirul,¹ Thanitsara Rittiphairoj,² Irin Lertparinyaphorn,³
5 Areerat Suputtitada⁴

6

7 **Author Affiliations**

8 ¹Department of Preventive and Social Medicine, Chulalongkorn University, Bangkok, Thailand

9 ²Department of Epidemiology, Harvard University, Massachusetts, USA

10 ³Department of Anatomical Pathology, Chulalongkorn University, Bangkok, Thailand

11 ⁴Department of Rehabilitation Medicine, Chulalongkorn University, Bangkok, Thailand

12 **Corresponding Author**

13 Dr Krit Pongpirul, Department of Preventive and Social Medicine, Faculty of Medicine,

14 Chulalongkorn University, Bangkok, Thailand 10330; doctorkrit@gmail.com

15 **ORCID ID**

16 Tanawin Nopsopon 0000-0003-0428-973X (tnopsopon@gmail.com)

17 Krit Pongpirul 0000-0003-3818-9761 (doctorkrit@gmail.com)

18 Thanitsara Rittiphairoj 0000-0002-5460-0808 (thanitsara.r@gmail.com)

19 Irin Lertparinyaphorn 0000-0002-1388-0903 (i.lertparinyaphorn@gmail.com)

20 Areerat Suputtitada 0000-0002-9920-7188 (rehabchula@gmail.com)

21 **Word count** This article contains 3,684 words. Abstract contains 247 words.

22 **ABSTRACT**

23 **Background** Intra-articular facet joint injection (FJI) has been increasingly used as a treatment for chronic low back
24 pain (LBP). Choice of the substance has been based on clinical experience with unclear evidence on marginal
25 effectiveness of active substance over normal saline as a placebo control. This systematic review investigates the
26 comparative effectiveness between normal saline and active substances on patient-reported outcomes (PROs).

27 **Methods** Systematic search was conducted in five databases: PubMed, Embase, Scopus, Web of Science, and
28 CENTRAL for randomized controlled trials and observational studies of evaluating the PROs of FJI comparing
29 active injected substances with normal saline as placebo in chronic LBP patients in the English language without
30 publication date restriction. Quality assessment was performed using ROB2 and ROBINS-I. The meta-analysis was
31 done using a random-effects model. Mean difference with 95% CIs of efficacy outcomes including pain, numbness,
32 disability, quality of life were measured.

33 **Results** Of 2,467 potential studies, three were included in the systematic review and meta-analysis (247 patients).
34 Compared to other active substances, normal saline provided similar therapeutic effects on pain outcome within one
35 hour (MD 2.43, 95% CI -11.61 to 16.50), at 1–1.5 months follow up (MD -0.63, 95% CI -7.97 to 6.72), and at 3 to
36 6 months (MD 1.90, 95% CI -16.03 to 19.83) as well as the quality of life at one and six months follow-up.

37 **Conclusions** The short-term and long-term clinical improvements of intra-articular FJI using normal saline are
38 comparable to the other active substances in LBP patients.

39 **PROSPERO** registration number CRD42020216426

40 **Keywords** Facet joint injection, Chronic low back pain, Normal saline, Meta-analysis

41

42 INTRODUCTION

43 Chronic low back pain (LBP) is a common health problem of individuals at some point in adult life.¹ Prevalence of
44 chronic LBP had an increasing trend with aging and affected about one-fifth of the global population who were aged
45 20–59.² Chronic LBP was the second leading cause of global work absence³ as well as the second most common
46 chief complaint presented at physician office⁴ accounted for about 2.3% of all ambulatory visits, approximately 20.5
47 million visits each year⁵ and cost exceed US\$100 billion per year in the United States.⁶

48 Non-operative treatments of chronic LBP were promoted as first-line treatment whereas a surgical option
49 was considered only when non-operative treatment was not available or failed.⁷ More recent studies showed no
50 superior long-term outcome of spinal fusion over non-operative treatment on pain and disability outcomes in patient
51 with chronic LBP.^{8 9} For non-invasive treatment, most guidelines recommended education, exercise, manual
52 therapy, multimodal rehabilitation, and oral medication including paracetamol, NSAIDs, and short-term opioids.^{10 11}
53 Intra-articular FJI, which was considered the most invasive treatment of non-operative treatment, has been
54 increasingly common^{12 13} despite no recommendation in most recent guidelines.^{7 14 15}

55 The intra-articular FJI was developed while the authors attempted to find the pain pattern of facet syndrome
56 used hypertonic saline and lidocaine as injected substances.¹⁶ Range of the injected substance options varied from
57 the commonly used mixture of steroid and local anesthesia,¹⁷ steroids alone,¹⁸ and local anesthesia alone¹⁹ to more
58 novel substances including ozone,²⁰ autologous platelet-rich plasma (PRP),²¹ as well as hyaluronic acid (HA).²²

59 Recent meta-analyses evaluated the therapeutic effects of intra-articular normal saline injection in knee
60 osteoarthritis found significant pain reduction effects on both short-term and long-term follow up.^{23 24} A network
61 meta-analysis that studied the effectiveness of various injected substances for intra-articular injection for hip
62 osteoarthritis presented that no active substance was superior to normal saline for pain reduction.²⁵ Nonetheless,
63 these findings might not be generalized to intra-articular injection for lumbar facet joints. Although recent
64 randomized controlled trials (RCTs) evaluating injected substances for intra-articular FJI usually compared novel
65 treatment with active control,^{21 22} some RCTs compared between active substances and normal saline as a placebo
66 control.¹⁸ Thus, evaluation regarding whether the efficacy and effectiveness demonstrated in normal saline intra-
67 articular injection in the knee and the hip also showed therapeutic effects in the facet joint can be conducted. In this

68 review, we performed a meta-analysis to evaluate whether intra-articular FJI with normal saline is similar to, if not
69 better than, active substances for patient-reported outcomes (PROs).

70 **METHODS**

71 **Study protocol**

72 This study was conducted following the recommendations of the Preferred Reporting Items of Systematic Reviews
73 and Meta-analyses (PRISMA) statement. We registered the systematic review with PROSPERO International
74 Prospective Register of Ongoing Systematic Reviews (registration number: CRD42020216426).

75 **Search strategy**

76 PubMed, Embase, Scopus, Web of Science, and CENTRAL were used to search for articles published in the English
77 language up to 1 February 2020. The search strategy is presented in detail in the Supplement. Besides, the reference
78 lists of included articles will be searched, as well as related citations from other journals via Google Scholar.

79 **Study selection**

80 For this systematic review, we worked with an information specialist to design an appropriate search strategy to
81 identify original peer-reviewed articles of RCTs and observational studies evaluating the PROs including pain,
82 numbness, disability, quality of life, or complication outcomes of FJI comparing active injected substances with
83 normal saline as placebo in patients with a diagnosis of chronic LBP. Article screening was done by two
84 independent reviewers (TN and TR) for eligible studies. Discrepancies between the two reviewers were resolved by
85 consensus.

86 **Data extraction**

87 Data extraction was done by two independent reviewers (TN and IL) for published summary estimate data.
88 Discrepancies between the two reviewers were resolved by consensus. We extracted the following data: (1) study
89 characteristics (authors, year of publication, study type, journal name, contact information, country, and funding),
90 (2) patient characteristics (sample size, age, age at onset, gender, comorbidities, method of diagnosis, inclusion and
91 exclusion criteria, disease duration, location of back pain), (3) intervention (the type of injected active substances,
92 dosage or regimen of injected substances, type of imaging guide, co-intervention), (4) comparators (volume of

93 injected normal saline, approach technique, type of imaging guide, co-intervention), (5) outcomes (complete list of
94 the names of all measured outcomes, unit of measurement, follow-up time point, missing data) as well as any other
95 relevant information. All relevant text, tables, and figures were examined for data extraction. We contacted the
96 authors of the study with incompletely reported data. If the trial authors did not respond within 14 days, we
97 conducted analyses using the available data.

98 **Risk of bias assessment**

99 The authors worked independently to assess the risk of bias in the included trials using the Cochrane Risk of Bias
100 Tool 2.0 for RCT study.²⁶ We assessed the randomization process, deviations from intended intervention, missing
101 outcome data, measurement of the outcome, selection of the reported result. We Assigned each domain as a low risk
102 of bias, some concerns, and a high risk of bias. For non-randomized trials and observational studies, we used the
103 Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I) to Investigate the confounding, selection of
104 participants into the study, classification of interventions, deviations from intended interventions, missing data,
105 measurement of outcomes, selection of the reported results.²⁷ We assigned each domain as a low, moderate, serious,
106 critical risk of bias, and no information. As mentioned above, we contacted the authors if there was insufficient
107 information to assess. If the trial authors did not respond within 14 days, we conducted the assessment using
108 available data. We resolved the disagreement through discussion, we present the risk of bias assessment in figure 2.

109 **Statistical analysis**

110 The primary outcome was a visual analog scale (VAS) for the pain measurement tools. The outcomes measured
111 were the mean difference (MD) in the reduction of VAS between before and after treatment with an associated 95%
112 confidence interval (CI). Disability outcomes including Oswestry Disability Index (ODI) and Pain Disability
113 Questionnaire (PDQ) were also retrieved with numbness outcome, quality of life outcome, and adverse events when
114 reported. The results of the studies were included in the meta-analysis and presented in a forest plot, which also
115 showed statistical powers, confidence intervals, and heterogeneity. We assessed clinical and methodological
116 heterogeneity by examining participant characteristics, intervention regimen, type of intervention, follow-up period,
117 outcomes, and study design. We then assessed statistical heterogeneity using the I^2 and χ^2 statistics. We regarded
118 level of heterogeneity for I^2 statistic as defined in chapter 9 of the Cochrane Handbook for Systematic Reviews of
119 Interventions: 0–40% might not be important; 30–60% may represent moderate heterogeneity; 50–90% may

120 represent substantial heterogeneity; 75–100% considerable heterogeneity. For missing standard deviation, we
121 imputed the standard deviation as suggested in chapter 6 of the Cochrane Handbook for Systematic Reviews of
122 Interventions referred to Furukawa methods.²⁸ Sensitivity analysis was applied for an alternate method for imputing
123 standard deviation if applicable. The random-effects meta-analysis by DerSimonian and Laird method was used as
124 clinical, methodological, and statistical heterogeneity encountered. The meta-analysis was performed using Revman
125 5.3 (Cochrane Collaboration, Oxford, UK).

126 **RESULTS**

127 **Study selection**

128 The database search identified 2,467 potential records. After removing duplicates, 1,305 titles passed the initial
129 Screen and 112 theme-related abstracts were selected for further full-text articles assessed for eligibility (figure 1). A
130 total of 109 articles were excluded as the following: 47 wrong study designs, 24 wrong comparators, 23 non-peer-
131 reviewed, six protocol, three duplicate, three non-English, two wrong intervention, and one wrong outcome. Only
132 three studies were eligible for our inclusion criteria.

133 (insert figure 1 about here)

134 **Study characteristics**

135 The three included studies were published between 1989 and 1998 (table 1).^{18 29 30} There were three RCTs and zero
136 non-randomized studies. The number of patients per study ranged from 70 to 97, with a total of 247 patients (137 of
137 them were females, 55.5%). The mean age of included patient varied from 43-58 years. Two studies reported disease
138 duration varied from a mean of 19.6 months, a median of 18 months in the intervention group, and a median of 24
139 months in the normal saline group. None of the included studies documented the co-morbidity and age at onset.
140 Carette study was the only study reported the co-intervention involved 11 patients in corticosteroid and six patients
141 in the placebo group.¹⁸ The included patients had a chronic LBP for over three to six months. The location of back
142 pain also varied with L3/L4 to L5/S1. The follow-up period ranged from 0.5 hours to 6 months.

143

144 **Table 1** Characteristics of the included studies

	Country	Interventions	Sample size	Disease duration (months)	Female ; n (%)	Age; mean (range)	Imaging technique	Patient reported outcomes				
								Pain	Disability	Numbness	Quality of Life	Adverse events
Lilius	Finland	(1) 6 ml bupivacaine hydrochloride mixed with 2 ml methylprednisolone acetate (2) 8 ml physiological saline	70	NR	39 (56%)	44 (19–64)	Fluoroscopy	VAS	Objective disability score (Only overall result)	NR	NR	7 Overall (5 men, 2 women)
Carette	Canada	(1) 1 ml methyl prednisolone acetate mixed with 1 ml of isotonic saline (2) 2 ml isotonic saline	97	(1) median 18 months (2) median 24 months	44 (45%)	43	Fluoroscopy	VAS	NR	NR	SIPs	No adverse events occurred
Revel	France	(1) 1 ml 2% lidocaine (2) 1 ml normal saline	80	Overall mean 19.6 months	54 (68%)	58 (34–87)	Fluoroscopy	VAS	NR	NR	NR	NR

145 NR, not reported; VAS, visual analog scale.

146 None of the three RCTs had the same type of active substances in the intervention arm. One study had a
 147 mixture of corticosteroid and local anesthesia as the intervention.²⁹ One study used corticosteroid alone while the
 148 other one used local anesthesia alone.^{18 30} All three trials used fluoroscopy-guided for FJI.

149 **Quality Assessment**

150 For the risk of bias assessment, the three randomized controlled trials included in this study had adequate
 151 randomization process in one trial, ensured deviations from intended interventions in two trials, ensured missing
 152 outcome data in two trials, adequate measurement of the outcome in three trials, and ensured the selection of the
 153 reported result in one trial.^{18 29 30} Only a high risk of bias in the selection of the reported result presented in one trial.
 154 A summary of the risk of bias assessment of randomized controlled trials which were at low, some concerns, and
 155 high risk for each risk of bias domain was presented in figure 2.

156 (insert figure 2 about here)

157

158 **Qualitative analysis**

159 The primary outcome assessed by visual analog pain scale (VAS) has been examined in all included studies,
160 consisted of three randomized controlled trials with a total number of 247 patients. Only Lilius study reported
161 disability outcome using a combined score proposed by the authors on a whole study group, but it was not reported
162 disability outcome for each intervention group.²⁹ Carette study reported no difference between corticosteroid and
163 normal saline FJI in overall quality of life outcome using Sickness Impact Profile (SIP) score which consisted of
164 physical and psychosocial dimensions both on one and six months follow up while only significant difference was
165 reported on the physical dimension on six months follow up with a favorable on corticosteroid injection (mean
166 difference (MD) -3.5, 95% CI -6.2 to -0.9).¹⁸ Two studies reported adverse events.^{18 29} Lilius study reported seven
167 overall adverse events, five in men and two in women,²⁹ while Carette study reported no major adverse event related
168 to intra-articular FJI.¹⁸ Unfortunately, only one study reported the eligible result in each outcome, therefore the
169 meta-analysis could not be conducted for the disability, quality of life, and adverse event outcomes. None of the
170 three included trials investigated numbness outcome.

171 Lilius study demonstrated a significant reduction of subjective pain for all participants at all follow-up
172 points (one hour, two weeks, six weeks, and three months), but there was no significant difference in subjective
173 visual pain scale reduction for intra-articular injection with a mixture of local anesthesia and steroid compared with
174 the intra-articular normal saline injection for facet joint L3/4 to L5/S1 for both short-term and long-term response
175 range from one hour to three months after injection.²⁹

176 Carette study demonstrated no difference between corticosteroid and normal saline injection in pain
177 measurement outcome using McGill pain questionnaire³¹ both one and six months follow up. The author also
178 investigated on self-rated pain assessment reported with very marked or marked improvement which was not a
179 significant difference on one month follow up, but patients treated with corticosteroid FJI reported a favorable
180 marked improvement on six months follow-up (MD 31%, 95% CI 14 to 48%).¹⁸

181 Revel study concluded that FJI with local anesthesia had a significant benefit in the change of pain score
182 over FJI with normal saline (p=0.01) in a specific patient group who met five or more of the seven clinical
183 characteristics proposed by the author consisted of 1) age greater than 65 years, 2) no pain exacerbation by cough, 3)
184 no pain exacerbation by forward-flexion, 4) no pain exacerbation when rising from flexion, 5) no pain exacerbation

185 by hyperextension, 6) no pain exacerbation by extension-rotation, and 7) pain well relieved by recumbent. For the
186 patient who did not meet five items of the criteria, FJI with normal saline showed a trend of better pain
187 improvement, although not significantly.³⁰

188 **Quantitative analysis**

189 All three studies, which reported the pain outcome assessed by visual analog pain scale, were included in the meta-
190 analysis.^{18 29 30} Revel study showed a significantly favorable outcome with VAS reduction after FJI with local
191 anesthesia within one hour follow up,³⁰ whereas Lilius study showed a trend of the benefit in favor the treatment
192 with normal saline injection; however, it was not significantly.²⁹ The pooled effect of two randomized controlled
193 trials showed no difference in pain reduction within one hour follow up between FJI with active substances and
194 normal saline (MD 2.43, 95% CI -11.61 to 16.50) (figure 3).

195 (insert figure 3 about here)

196 Lilius and Carette studies reported no difference in pain diminishing between active substances and normal
197 saline FJI as placebo with 1–1.5 months follow up.^{18 29} The meta-analysis of the two studies showed a similar result;
198 the mean difference was -0.63 (95% CI -7.97 to 6.72) (figure 4).

199 (insert figure 4 about here)

200 Two studies reported long-term follow-up in pain scores ranged from 3 to 6 months. Lilius study reported a
201 significantly favorable benefit of normal saline over active substance on long-term pain reduction²⁹ while Carette
202 study reported a significantly favorable benefit of corticosteroid over placebo intra-articular FJI on long-term pain
203 reduction.¹⁸ The pooled effects of long-term pain reduction after FJI showed no difference between injected with
204 active substances and injected with normal saline as placebo (MD 1.90, 95% CI
205 -16.03 to 19.83) (figure 5).

206 (insert figure 5 about here)

207 Sensitivity analysis was performed with an alternative method of standard deviation imputation using
208 standard deviation from the included study in this meta-analysis instead of from the previous meta-analysis. The

209 pooled effect of pain reduction within one hour, with 1–1.5 months follow up, and with long-term follow up was
210 similar to the main imputation method (online supplementary file).

211 **DISCUSSION**

212 Our meta-analysis suggests that the treatment with normal saline intra-articular FJI as placebo provided similar
213 effectiveness to intra-articular FJI with active substance for patient-reported pain outcome measured by visual
214 analog pain scales at all studied time point ranged from 0.5 hours to six months after FJI.

215 It is hard to conclude from the trials because of the heterogeneity presented in the age of population targets,
216 type of active substance, location of back pain, follow-up time, and outcome measurements. The findings suggested
217 no difference in the pain reduction benefit between FJI with normal saline and with active substances for chronic
218 LBP patients; however, they needed more robustness to provide a high level of evidence.

219 Lilius study showed significant pain reduction for both saline and steroid with local anesthesia FJIs while
220 no significant differences between intra-articular saline and intra-articular steroid with local anesthesia injection on
221 subjective pain scale at all follow-up ranged from one hour to three months. One-fourth of subjects experienced pain
222 reduction benefit up to three months after FJI and overall disability score was significantly improved regardless of
223 the injected substance. The therapeutic effect of saline was unexpected, and only suggestion on the psychosocial
224 point of view and self-regression had been provided without clear evidence and explanation.²⁹

225 Carette study demonstrated a similar LBP reduction effect of corticosteroid FJI to normal saline FJI at one-
226 and six-months follow-up evaluated with visual analog pain scale and McGill pain questionnaire. The authors
227 conclude that FJI with corticosteroid provided little benefit to patients with chronic LBP with the belief that normal
228 saline injection was a true placebo. Moreover, this study was the only one in meta-analysis assessed the quality of
229 life outcome using Sickness Impact Profile score with the only favorable effect of steroid could be observed for
230 physical dimension at six months follow up, but not for psychosocial dimension.¹⁸

231 Revel study explored the characteristics of chronic LBP patients which were significant predictors of a
232 favorable pain reduction of local anesthesia intra-articular FJI compared to saline FJI which consisted of five
233 characteristics of present back pain. Normal saline was considered as a true placebo and the therapeutic effect of

234 saline was suspected for inadequate diagnostic criteria which resulted in a false-positive selection of chronic LBP
235 patients who would potentially have benefited from FJI.³⁰

236 High-quality systematic review and meta-analysis had been conducted to identify injection therapy for
237 subacute and chronic LBP; only one study compared FJI with the active substance and with placebo¹⁸ had been
238 identified and included in a meta-analysis of pain outcome with self-compared between short-term and long-term
239 therapeutic effect which resulted in no significant difference.³² More recent systematic review attempt to compared
240 efficacy of saline, local anesthesia, and steroids in FJI also identified the same study¹⁸ without conducting meta-
241 analysis.³³ Thus, our study is the first meta-analysis conducted with more than one included study.

242 Two meta-analyses focused on the efficacy of intra-articular normal saline injection for knee osteoarthritis
243 demonstrated therapeutic effects of normal saline injection on pain^{23,24} and functional outcome;²⁴ however, the meta-
244 analyses conducted comparing pre-injection and post-injection, not between injected substance. Network meta-
245 analysis evaluated the effectiveness of various injected substance for intra-articular injection in patients with hip
246 osteoarthritis showed that intra-articular hip saline injection had similar effects to all other active substances on pain
247 and functional outcome.²⁵ These studies provided strong evidence for the potential therapeutic intra-articular saline
248 injection which were concordance with our findings, which cast the doubt on the appropriateness of using normal
249 saline intra-articular as true placebo and the result interpretation.

250 The paradox for practices of intra-articular FJI had occurred. No early trials could provide any significant
251 benefit of the active substance over normal saline as the placebo,^{18, 29, 30} resulted in lack of supporting evidence to
252 recommended the use of intra-articular FJI in guidelines;^{7, 14, 15} however, the trend of utilization intra-articular FJI in
253 real-world practices was increasing.¹³ Another paradox occurred for the choice of injected substance for intra-
254 articular FJI when more recent trials chose a combination of corticosteroid and local anesthesia²¹ or corticosteroid
255 alone²² as a comparator of a novel injected substance instead of normal saline as a true placebo comparator despite
256 no evidence of a superior benefit of local anesthesia or corticosteroid over the normal saline intra-articular FJI. The
257 result interpretation would have a serious problem, especially when no significant difference was observed: a novel
258 substance has a similar effect to corticosteroid or local anesthesia, or a combination of both which have similar
259 effect to normal saline, a true placebo. In the past, many authors considered that normal saline would actually be a
260 true placebo and concluded that there was no therapeutic benefit of intra-articular FJI on LBP.^{18, 30} Results from our

261 study might be a missing piece of jigsaw that there was plausible evidence demonstrated that normal saline was not
262 a true placebo, thus intra-articular FJI might have benefits for chronic LBP all along.

263 Normal saline therapeutic effect on pain reduction had been demonstrated in meta-analyses on
264 osteoarthritis of knee^{23 24} and hip.²⁵ However, the explanation of the effect had been rarely studied and mostly based
265 on hypothesis. One hypothesis is the dilution of inflammatory mediators which resulted in pain relief.³⁴ A study
266 attempted to explore the potential of other mechanisms including the osmolality effect and sodium concentration,
267 but no sufficient evidence to support the hypothesis.³⁵ For facet joint, the first saline injection which resulted in pain
268 relief was hypertonic saline.³⁶ Caterini study found that facet joint pain might originate from excessive facet joint
269 fluid,³⁷ thus this could be an explanation on how hypertonic saline could relieve facet joint pain, but not for normal
270 saline. The osmolality effect might come into account since facet joint pain could originate from various causes,
271 there might be some type of facet joint pain that the patients had a normal volume of facet joint fluid but had
272 imbalance osmolality. This is merely one of the hypotheses since no available study on this question.

273 There were several limitations in this meta-analysis. First, the presence of heterogeneous characteristics of
274 the patients, type of injected substance, and timing of outcome assessment led to difficulty for the conclusion of the
275 data. Second, some trials did not report the standard deviation needed for the meta-analysis, thus techniques of the
276 imputation of missing standard deviation had been used which might not reflect the real variation in outcome for the
277 study. Third, there was a small number of studies focused on injected substance for intra-articular FJI which led to
278 only a few studies has been included in the meta-analysis and some PROs had insufficient outcome to conduct a
279 meta-analysis. Fourth, there was surprisingly no new trial compared active substance and normal saline for twenty
280 years. The evidence might not be completely comparable to present practices for intra-articular JFI; however, this
281 study provided the most up-to-date pieces of evidence to shed light on the therapeutic effects of intra-articular
282 normal saline FJI.

283 In conclusion, this systematic review and meta-analysis suggests that the short-term and long-term clinical
284 improvements of intra-articular FJI using normal saline are comparable to the other active substances in LBP
285 patients.

286

287 **Contributors** TN took part in design of this project, acquisition of data, analysis and interpretation of data, and
288 writing the manuscript. KP took part in conception and design of this project, interpretation of data, and writing the
289 manuscript. TR took part in acquisition of data, interpretation of data, and writing the manuscript. IL took part in
290 interpretation of data and writing the manuscript. AS took part in conception and design of this project, and writing
291 the manuscript.

292 **Funding** The authors have not declared a specific grant for this research from any funding agency in the public,
293 commercial or not-for-profit sectors.

294 **Competing interests** None declared.

295 **Patient consent for publication** Not required.

296 **Data availability statement** Data are available on reasonable request.

297

298 References

- 299 1. Andersson G. Epidemiological features of chronic low-back pain. *Lancet* 1999;354(9178):581-5. doi:
300 10.1016/s0140-6736(99)01312-4 [published Online First: 1999/09/02]
- 301 2. Meucci R, Fassa A, Faria N. Prevalence of chronic low back pain: systematic review. *Rev Saude Publica*
302 2015;49:1. doi: 10.1590/s0034-8910.2015049005874 [published Online First: 2015/10/22]
- 303 3. Lidgren L. The bone and joint decade 2000-2010. *Bull World Health Organ* 2003;81(9):629. [published Online
304 First: 2004/01/09]
- 305 4. Golob A, Wipf J. Low back pain. *Med Clin North Am* 2014;98(3):405-28. doi: 10.1016/j.mcna.2014.01.003
306 [published Online First: 2014/04/25]
- 307 5. Deyo R, Mirza S, Martin B. Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002.
308 *Spine (Phila Pa 1976)* 2006;31(23):2724-7. doi: 10.1097/01.brs.0000244618.06877.cd [published Online First:
309 2006/11/02]
- 310 6. Katz J. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. *J Bone Joint Surg Am*
311 2006;88 Suppl 2:21-4. doi: 10.2106/jbjs.E.01273 [published Online First: 2006/04/06]
- 312 7. Airaksinen O, Brox J, Cedraschi C, et al. Chapter 4. European guidelines for the management of chronic
313 nonspecific low back pain. *Eur Spine J* 2006;15 Suppl 2(Suppl 2):S192-300. doi: 10.1007/s00586-006-1072-1
314 [published Online First: 2006/03/22]
- 315 8. Hedlund R, Johansson C, Hägg O, et al. The long-term outcome of lumbar fusion in the Swedish lumbar spine
316 study. *Spine J* 2016;16(5):579-87. doi: 10.1016/j.spinee.2015.08.065 [published Online First: 2015/09/13]
- 317 9. Mannion A, Brox J, Fairbank J. Consensus at last! Long-term results of all randomized controlled trials show that
318 fusion is no better than non-operative care in improving pain and disability in chronic low back pain. *Spine J*
319 2016;16(5):588-90. doi: 10.1016/j.spinee.2015.12.001 [published Online First: 2016/06/05]
- 320 10. Wong J, Côté P, Sutton D, et al. Clinical practice guidelines for the noninvasive management of low back pain:
321 A systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMA) Collaboration. *Eur J*
322 *Pain* 2017;21(2):201-16. doi: 10.1002/ejp.931 [published Online First: 2016/10/07]
- 323 11. Oliveira C, Maher C, Pinto R, et al. Clinical practice guidelines for the management of non-specific low back
324 pain in primary care: an updated overview. *Eur Spine J* 2018;27(11):2791-803. doi: 10.1007/s00586-018-5673-2
325 [published Online First: 2018/07/05]
- 326 12. Mars T, Ellard D, Antrobus J, et al. Intraarticular Facet Injections for Low Back Pain: Design Considerations,
327 Consensus Methodology to Develop the Protocol for a Randomized Controlled Trial. *Pain Physician*
328 2015;18(5):473-93. [published Online First: 2015/10/03]
- 329 13. Manchikanti L, Pampati V, Singh V, et al. Assessment of the escalating growth of facet joint interventions in the
330 medicare population in the United States from 2000 to 2011. *Pain Physician* 2013;16(4):E365-78. [published
331 Online First: 2013/07/24]
- 332 14. Chou R, Loeser J, Owens D, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low
333 back pain: an evidence-based clinical practice guideline from the American Pain Society. *Spine (Phila Pa 1976)*
334 2009;34(10):1066-77. doi: 10.1097/BRS.0b013e3181a1390d [published Online First: 2009/04/14]
- 335 15. National Guideline C. National Institute for Health and Care Excellence: Clinical Guidelines. Low Back Pain
336 and Sciatica in Over 16s: Assessment and Management. London: National Institute for Health and Care
337 Excellence (UK) Copyright © NICE, 2016.
- 338 16. Mooney V, Robertson J. The facet syndrome. *Clin Orthop Relat Res* 1976(115):149-56. [published Online First:
339 1976/03/01]
- 340 17. Lau L, Littlejohn G, Miller M. Clinical evaluation of intra-articular injections for lumbar facet joint pain. *Med J*
341 *Aust* 1985;143(12-13):563-5. [published Online First: 1985/12/09]
- 342 18. Carette S, Marcoux S, Truchon R, et al. A controlled trial of corticosteroid injections into facet joints for chronic
343 low back pain. *N Engl J Med* 1991;325(14):1002-7. doi: 10.1056/nejm199110033251405 [published Online
344 First: 1991/10/03]
- 345 19. Schwarzer A, Aprill C, Derby R, et al. Clinical features of patients with pain stemming from the lumbar
346 zygapophysial joints. Is the lumbar facet syndrome a clinical entity? *Spine (Phila Pa 1976)* 1994;19(10):1132-7.
347 doi: 10.1097/00007632-199405001-00006 [published Online First: 1994/05/15]
- 348 20. Bonetti M, Fontana A, Martinelli F, et al. Ozone Injection Therapy for Lumbar Facet Joint Syndrome. A
349 prospective study. *International Journal of Ozone Therapy* 2008;7:16-20.
- 350 21. Wu J, Du Z, Lv Y, et al. A New Technique for the Treatment of Lumbar Facet Joint Syndrome Using Intra-
351 articular Injection with Autologous Platelet Rich Plasma. *Pain Physician* 2016;19(8):617-25. [published Online

- 352 First: 2016/12/03]
- 353 22. Annaswamy T, Armstead C, Carlson L, et al. Intra-articular Triamcinolone Versus Hyaluronate Injections for
- 354 Low Back Pain With Symptoms Suggestive of Lumbar Zygapophyseal Joint Arthropathy: A Pragmatic, Double-
- 355 Blind Randomized Controlled Trial. *Am J Phys Med Rehabil* 2018;97(4):278-84. doi:
- 356 10.1097/phm.0000000000000879 [published Online First: 2017/12/21]
- 357 23. Altman R, Devji T, Bhandari M, et al. Clinical benefit of intra-articular saline as a comparator in clinical trials of
- 358 knee osteoarthritis treatments: A systematic review and meta-analysis of randomized trials. *Semin Arthritis*
- 359 *Rheum* 2016;46(2):151-59. doi: 10.1016/j.semarthrit.2016.04.003 [published Online First: 2016/05/31]
- 360 24. Saltzman B, Leroux T, Meyer M, et al. The Therapeutic Effect of Intra-articular Normal Saline Injections for
- 361 Knee Osteoarthritis: A Meta-analysis of Evidence Level 1 Studies. *Am J Sports Med* 2017;45(11):2647-53. doi:
- 362 10.1177/0363546516680607 [published Online First: 2016/12/29]
- 363 25. Gazendam A, Ekhtiari S, Bozzo A, et al. Intra-articular saline injection as effective as corticosteroids, platelet-
- 364 rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of
- 365 randomised controlled trials. *Br J Sports Med* 2020 doi: 10.1136/bjsports-2020-102179 [published Online First:
- 366 2020/08/24]
- 367 26. Sterne J, Savović J, Page M, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *Bmj*
- 368 2019;366:l4898. doi: 10.1136/bmj.l4898 [published Online First: 2019/08/30]
- 369 27. Sterne J, Hernán M, Reeves B, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of
- 370 interventions. *Bmj* 2016;355:i4919. doi: 10.1136/bmj.i4919 [published Online First: 2016/10/14]
- 371 28. Furukawa T, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide
- 372 accurate results. *J Clin Epidemiol* 2006;59(1):7-10. doi: 10.1016/j.jclinepi.2005.06.006 [published Online First:
- 373 2005/12/20]
- 374 29. Lilius G, Laasonen E, Myllynen P, et al. Lumbar facet joint syndrome. A randomised clinical trial. *J Bone Joint*
- 375 *Surg Br* 1989;71(4):681-4. doi: 10.1302/0301-620x.71b4.2527856 [published Online First: 1989/08/01]
- 376 30. Revel M, Poiraudou S, Auleley G, et al. Capacity of the clinical picture to characterize low back pain relieved
- 377 by facet joint anesthesia. Proposed criteria to identify patients with painful facet joints. *Spine (Phila Pa 1976)*
- 378 1998;23(18):1972-6; discussion 77. doi: 10.1097/00007632-199809150-00011 [published Online First:
- 379 1998/10/21]
- 380 31. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. *Pain* 1975;1(3):277-99. doi:
- 381 10.1016/0304-3959(75)90044-5 [published Online First: 1975/09/01]
- 382 32. Nelemans P, de Bie R, de Vet H, et al. Injection therapy for subacute and chronic benign low back pain.
- 383 *Cochrane Database Syst Rev* 2000(2):Cd001824. doi: 10.1002/14651858.Cd001824 [published Online First:
- 384 2000/05/05]
- 385 33. Manchikanti L, Nampiaparampil D, Manchikanti K, et al. Comparison of the efficacy of saline, local anesthetics,
- 386 and steroids in epidural and facet joint injections for the management of spinal pain: A systematic review of
- 387 randomized controlled trials. *Surg Neurol Int* 2015;6(Suppl 4):S194-235. doi: 10.4103/2152-7806.156598
- 388 [published Online First: 2015/05/26]
- 389 34. Sit R, Wu R, Rabago D, et al. Efficacy of Intra-Articular Hypertonic Dextrose (Prolotherapy) for Knee
- 390 Osteoarthritis: A Randomized Controlled Trial. *Ann Fam Med* 2020;18(3):235-42. doi: 10.1370/afm.2520
- 391 [published Online First: 2020/05/13]
- 392 35. Bar-Or D, Rael L, Brody E. Use of Saline as a Placebo in Intra-articular Injections in Osteoarthritis: Potential
- 393 Contributions to Nociceptive Pain Relief. *Open Rheumatol J* 2017;11:16-22. doi:
- 394 10.2174/1874312901711010016 [published Online First: 2017/04/13]
- 395 36. Hirsch C, Ingelmark B, Miller M. The anatomical basis for low back pain. Studies on the presence of sensory
- 396 nerve endings in ligamentous, capsular and intervertebral disc structures in the human lumbar spine. *Acta Orthop*
- 397 *Scand* 1963;33:1-17. doi: 10.3109/17453676308999829 [published Online First: 1963/01/01]
- 398 37. Caterini R, Mancini F, Bisicchia S, et al. The correlation between exaggerated fluid in lumbar facet joints and
- 399 degenerative spondylolisthesis: prospective study of 52 patients. *J Orthop Traumatol* 2011;12(2):87-91. doi:
- 400 10.1007/s10195-011-0141-3 [published Online First: 2011/05/21]
- 401

403 **Figure legends**

404 **Figure 1** Flow chart diagram on how the studies were selected for analysis based on the Preferred Reporting Items
405 for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

406 **Figure 2** Risk of biases of included randomized controlled trials.


407 **Figure 3** Forest plot showing the effect of active substance versus normal saline on pain reduction within one hour.

408 **Figure 4** Forest plot showing the effect of active substance versus normal saline on pain reduction at 1–1.5 months
409 follow-up visit.

410 **Figure 5** Forest plot showing the effect of active substance versus normal saline on pain reduction at 3–6 months
411 follow-up visit.



PRISMA 2009 Flow Diagram



	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result
Lilius 1989	?	?	?	+	?
Carette 1991	+	+	+	+	+
Revel 1998	?	+	+	+	-

